转移性乳腺癌中HER2低表达的瘤内与转移灶间异质性
本研究基于死后组织捐献项目UPTIDER,对10例HER2阴性转移性乳腺癌患者的257个转移灶和8个乳腺肿瘤行中心HER2免疫组化检测,并按ASCO/CAP 2018指南分类。结果显示HER2低表达状态存在显著的转移灶间异质性,8/10例患者中HER2低表达与HER2零表达转移灶共存,HER2低表达病灶比例范围为5%至89%。
要点
- 8/10例患者中HER2低表达与HER2零表达转移灶共存,HER2低表达病灶比例5%至89%。
- 当前分类为HER2零表达的转移灶中32%为HER2超低表达。
- 原发性ER阳性患者HER2低表达转移灶比例高于ER阴性患者(46% vs 8%)。
核心结论
- HER2低表达状态存在显著的瘤内转移灶间异质性,这质疑了HER2低表达在当前形式下作为诊疗标志物的有效性。
研究设计与样本
- 纳入10例HER2阴性转移性乳腺癌患者(7例ER阳性,3例ER阴性),样本来自死后组织捐献项目UPTIDER。
- 对257个转移灶和8个乳腺肿瘤的切除性死后活检样本行中心HER2免疫组化检测,另检测41份死前原发或转移样本。
- 按ASCO/CAP 2018指南将样本分类为HER2零表达、HER2低表达(HER2-1+或HER2-2+且原位杂交[ISH]阴性)或HER2阳性(HER2-3+或HER2-2+且ISH阳性)。
- HER2零表达进一步分为HER2未检测到(无染色)和HER2超低表达(≤10%肿瘤细胞微弱染色)。
主要发现
- 死后间隔时间中位数为2.5小时。
- 8/10例患者中HER2低表达和HER2零表达转移灶共存,HER2低表达病灶比例范围为5%至89%。
- 当前分类为HER2零表达的转移灶中32%为HER2超低表达。
- 肝脏中3/6例患者观察到HER2评分的器官内转移灶间异质性。
- 原发性ER阳性患者HER2低表达转移灶比例高于ER阴性患者(46% vs 8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-HER2 antibody-drug conjugates (ADCs) have shown important efficacy in HER2-low metastatic breast cancer (mBC). Criteria for receiving ADCs are based on a single assay on the primary tumour or a small metastatic biopsy. We assessed the intra-patient inter-metastasis heterogeneity of HER2-low status in HER2-negative mBC. PATIENTS AND METHODS: We included samples of 10 patients (7 ER-positive and 3 ER-negative) donated in the context of our post-mortem tissue donation program UPTIDER. Excisional post-mortem biopsies of 257 metastases and 8 breast tumours underwent central HER2 immunohistochemistry (IHC), alongside 41 pre-mortem primary or metastatic samples. They were classified as HER2-zero, HER2-low (HER2-1+ or HER2-2+, in situ hybridisation [ISH] negative) or HER2-positive (HER2-3+ or HER2-2+, ISH-positive) following ASCO/CAP guidelines 2018. HER2-zero was further subdivided into HER2-undetected (no staining) and HER2-ultralow (faint staining in ≤10% of tumour cells). RESULTS: Median post-mortem interval was 2.5 h. In 8/10 patients, HER2-low and HER2-zero metastases co-existed, with the proportion of HER2-low lesions ranging from 5% to 89%. A total of 32% of metastases currently classified as HER2-zero were HER2-ultralow. Intra-organ inter-metastasis heterogeneity of HER2-scores was observed in the liver in 3/6 patients. Patients with primary ER-positive disease had a higher proportion of HER2-low metastases as compared to ER-negative disease (46% versus 8%, respectively). At the metastasis level, higher percentages of ER-expressing cells were observed in HER2-low or -ultralow as compared to HER2-undetected metastases. CONCLUSIONS: Important intra-patient inter-metastasis heterogeneity of HER2-low status exists. This questions the validity of HER2-low in its current form as a theranostic marker.
引用
- Geukens T, De Schepper M, Richard F, et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur J Cancer. 2023. PMID: 37247580. doi:10.1016/j.ejca.2023.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。